Table 2.
PMSA PET/CT scan versus CT abdomen pelvis and BS.
| Positive | Negative | |
|---|---|---|
| Bone metastases, n (%) | ||
| PSMA PET/CT | 70 (18.2) | 314 (81.8) |
| BS | 51 (13.2) | 333 (86.8) |
| p-Value | 0.074 | |
| Local recurrence, n (%) | ||
| PSMA PET/CT | 77 (20.1) | 307 (79.9) |
| CTAP | 70 (18.2) | 314 (81.8) |
| p-Value | 0.52 | |
| Distant metastases, n (%) | ||
| PSMA PET/CT | 206 (53.6) | 178 (46.4) |
| CTAP and BS | 114 (29.7) | 270 (70.3) |
| p-Value | <0.001 | |
| Radiological positive lesions (local and distant disease), n (%) | ||
| PSMA | 245 (63.8) | 139 (36.2) |
| CTAP and BS | 174 (45.3) | 210 (54.7) |
| p-Value | <0.001 | |
BS, bone scan; CT, computed tomography; CTAP, CT abdomen/pelvis; PET/CT, positron emission tomography/computed tomography; PSMA, prostate-specific membrane antigen.